Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication
This case report centres on the post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in the case of a 27-year-old man found dead after falling from the 24th floor of a high-rise building. Toxicological analysis of post-mortem samples confirmed, besides consumption of the synthetic cannabinoids MDMB-CHMICA (1.7 ng/mL femoral blood) and EG-018, the abuse of THC (9.3 ng/mL femoral blood), amphetamine (1050 ng/mL femoral blood), MDMA (275 ng/mL femoral blood), and cocaine. Regarding EG-018 and cocaine, only traces were detected in heart blood as well as in the brain (EG-018) and urine (cocaine), respectively, which is why no quantification was conducted in the femoral blood sample. It was concluded from femoral blood analysis that, at the time of death, the man was under the influence of the synthetic cannabinoid MDMB-CHMICA, THC, amphetamine and MDMA. Comprehensive screenings of all post-mortem specimens were conducted to elucidate the post-mortem distribution of MDMB-CHMICA and its metabolites. The MDMB-CHMICA concentrations ranged between 0.01 ng/mL (urine) and 5.5 ng/g (brain). Comparably low concentrations were detected in cardiac and femoral blood (2.1 ng/mL and 1.7 ng/mL, respectively) as well as in the psoas major muscle (1.2 ng/g). Higher concentrations were found in the lung (2.6 ng/g), liver (2.6 ng/g), and kidney (3.8 ng/g). Gastric content yielded a MDMB-CHMICA concentration of 2.4 ng/g (1.1 μg absolute). Screening for MDMB-CHMICA metabolites resulted in the detection of mainly monohydroxylated metabolites in the blood, kidney, and liver specimens. Results indicated that monohydroxylated metabolites of MDMB-CHMICA are appropriate target analytes for detecting MDMB-CHMICA intake.
KeywordsSynthetic cannabinoids Post-mortem distribution Standard addition MDMB-CHMICA Metabolites
The authors wish to thank the laboratory staff for performing the routine systematic toxicological analysis. In addition, the authors thank Tobias Kieliba and Sibylle Banaschak (Institute of Legal Medicine, Medical Faculty, University of Cologne) for technical support. Special thanks are directed to June Mercer-Chalmers-Bender for editorial support and English language editing.
This project was funded by the German Federal Ministry for Economic Affairs and Energy and ZIM (Central Innovations Programs for Medium-sized enterprises) (KF2429613MD3) and the German ‘Bund gegen Alkohol und Drogen im Straßenverkehr e.V.’ (a non-profit association against alcohol and drugs on the road).
Compliance with ethical standards
Compliance with the law
All experiments comply with the current laws of the Federal Republic of Germany. The public prosecutor’s office and the legal representative of the deceased gave permission for this case to be published.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JBC, Glass M, McGregor IS, Connor M, Kassiou M (2016) Pharmacology of Valinate and tert-Leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 7:1241–1254. https://doi.org/10.1021/acschemneuro.6b00137 CrossRefPubMedGoogle Scholar
- 2.Hill SL, Najafi J, Dunn M, Acheampong P, Kamour A, Grundlingh J, Blain PG, Thomas SHL (2016) Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the identification of novel psychoActive substances (IONA) study. Clin Toxicol 54(8):638–643. https://doi.org/10.1080/15563650.2016.1190980 CrossRefGoogle Scholar
- 3.Hermanns-Clausen M, Müller D, Kithinji J, Angerer V, Franz F, Eyer F, Neurath H, Liebetrau G, Auwärter V (2017) Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMBCHMICA. Clin Toxicol 56:404–411. https://doi.org/10.1080/15563650.2017.1393082 CrossRefGoogle Scholar
- 4.EMCDDA (2016) EU early warning system alert - MDMB CHMICAGoogle Scholar
- 5.EMCDDA/EUROPOL (2016) Europol Joint Report - MDMB CHMICAGoogle Scholar
- 13.Kronstrand R, Tyrkko E, Lindstedt D, Roman M (2015) Poster P103: MMB-CHMINACA blood concentrations in recreational users and fatal intoxications. Paper presented at the 53rd the International Association of Forensic Toxicologists (TIAFT) meeting, Firenze, ItalyGoogle Scholar
- 14.Franz F, Schwörer N, Angerer V, Moosmann B, Auwarter V (2015) Metabolism and urine analysis of the new synthetic cannabinoid MDMB-CHMICA. Toxichem Krimtech 192(82):1–7Google Scholar
- 17.Madea B (2015) Rechtsmedizin (in German), vol 3. Springer VerlagGoogle Scholar
- 19.Gaunitz F, Schürenkamp J, Rostamzadeh A, Konkol C, Thevis M, Rothschild MA, Mercer-Chalmers-Bender K (2017) Analysis of taxine B/isotaxine B in a plasma specimen by LC–MS/MS in a case of fatal poisoning: concealed suicide by ingestion of yew (Taxus L.) leaves of a patient with a long-term history of borderline personality disorder. Forensic Toxicol 35(2):421–427. https://doi.org/10.1007/s11419-017-0355-z CrossRefGoogle Scholar
- 21.Lehmann S, Kieliba T, Beike J, Thevis M, Mercer-Chalmers-Bender K (2017) Determination of 74 new psychoactive substances in serum using automated in-line solid-phase extraction-liquid chromatography-tandem mass spectrometry. J Chromatogr B (accepted for publication) 1064:124–138. https://doi.org/10.1016/j.jchromb.2017.09.003 CrossRefGoogle Scholar
- 24.Baselt RC (2011) Disposition of toxic drugs and chemicals in man, vol 9. Biomedical PublicationsGoogle Scholar
- 27.Kalant H (2001) The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAI 165(7):917–928Google Scholar
- 33.Taylor KB (1973) Dopamine-β-hydroxylase: stereochemical course of the reaction. J Biol Chem 249(2):454–458Google Scholar
- 35.Feio-Azevedo R, Costa VM, Ferreira LM, Branco PS, Pereira FC, Bastos ML, Carvalho F, Capela JP (2017) Toxicity of the amphetamine metabolites 4-hydroxyamphetamine and 4-hydroxynorephedrine in human dopaminergic differentiated SH-SY5Y cells. Toxicol Lett 269:65–76. https://doi.org/10.1016/j.toxlet.2017.01.012 CrossRefPubMedGoogle Scholar
- 39.Fabritius M, Favrat B, Chtioui H, Battistella G, Annoni J-M, Appenzeller M, Dao K, Fornari E, Lauer E, Mall J-F, Maeder P, Mangin P, Stauba C, Girouda C (2014) THCCOOH concentrations in whole blood: are they useful in discriminating occasional from heavy smokers? Drug Test Anal 6:155–163CrossRefPubMedGoogle Scholar